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Introduction
A chylothorax can be defined as a leakage of chylous fluid from 
an abnormal or damaged thoracic duct or a main branch thereof, 
after an injury or obstruction in the pleural cavity. Management of 
a chylothorax includes surgical and conservative medical treatment 
that includes medical nutrition therapy. However, there is no clear 
evidence yet as to whether enteral nutrition or parenteral nutrition is 
the preferred nutrition support option for medical nutrition therapy.
Case report
Mr J, a 34-year-old man presented at the emergency care unit of 
the hospital with a stab wound to the neck above the fifth thoracic 
vertebra. The patient had no other known diseases or allergies, and 
had a previous hospital admission because of an assault. He was 
responsive and cooperative, but had difficulty talking because of the 
trauma. He reported that he drank occasionally at social events and 
exercised regularly. 
The patient complained of chest discomfort and shortness of 
breath. He subsequently underwent a chest X-ray and a computed 
tomography angiogram, which confirmed a pleural effusion on the 
left side of the chest. An intercostal drain was inserted to drain the 
pleural fluid which appeared milky. 
Diagnosis
The patient was diagnosed with a chylothorax due to a penetrating 
trauma to the neck. 
Anthropometry
On admission, he weighed 55 kg and had a body mass index (BMI) of 
17.3 kg/m2, from which the patient was classified as underweight.1 
His mid-upper-arm circumference (MUAC) and triceps skinfold were 
measured, from which his arm muscle area and arm fat area were 
determined. The patient presented with poor muscle and fat stores, 
as evident from his MUAC of 22.5 cm, which was below the fifth 
percentile according to the National Health and Nutrition Examination 
Survey percentile tables.2,3 His arm muscle area also fell below the 
fifth percentile, and his arm fat area was between the fifth and the 
tenth percentile.4 The patient’s ideal weight was determined at a BMI 
of 20 kg/m2 to be 63 kg.
Biochemistry
The initial biochemistry values obtained for the patient are shown 
in Table I. The observed hyponatraemia and hypochloraemia most 
probably resulted from the increased sodium losses from the chyle 
leak and is characteristic in a diagnosis of chylothorax.5-7 Serum 
creatinine levels reflect muscle mass as it is mostly derived from the 
breakdown of endogenous sources, and less affected by catabolic 
states than urea levels. Thus, the decreased creatinine levels reflect 
low muscle mass in this patient which corresponded with the poor 
muscle stores observed using the anthropometric indicators. Urea, 
on the other hand, is derived from either dietary protein sources or 
endogenous protein sources and its formation influenced by protein 
intake, increased catabolism (either due to starvation or an acute 
phase response), as well as the absorption of protein from the blood 
in the gastrointestinal lumen. Although a decreased urea level can 
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Initial patient biochemical 
values
Na 135-145 mmol/l 129 mmol/l
K 3.3-5.2 mmol/l 3.5 mmol/l
Cl 99-113 mmol/l 95 mmol/l
CO2 19-29 mmol/l 25 mmol/l
Urea 2.6-8 mmol/l 1.9 mmol/l
Creat 60-100 mmol/l 54 mmol/l
CRP 0-10 mg/l 45 mg/l
Hb 12.1-16.3 g/dL 10.2 g/dl
Hb: haemoglobin, Cl chloride, C02: carbon dioxide, Creat: creatinine, CRP: C-reactive protein, K: 
potassium, Na: sodium
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reflect a low protein intake, the most common cause of decreased 
urea levels in hospitals is overenthusiastic intravenous infusion of 
maintenance fluid.8 There was also evidence of an ongoing acute 
phase response, as observed from the elevated C-reactive protein 
levels, the latter being a non-specific acute phase protein with a 
short half-life of 5-7 hours. 7
Clinical
The patient appeared wasted, with unremarkable vital signs. His 
intercostal drainage was 360 ml over a 24-hour period.
The patient was prescribed Clexane®, Fragmin®, Omnopon® and 
Panado®.
Dietary
The patient was kept nil per os and Ringer’s lactate infused 
intravenously at 100 ml/hour. Total parenteral nutrition (TPN) was 
requested since there was concern that enteral nutrition could 
exacerbate the chyle leak, even though the intercostal drainage was 
only 360 ml.
The European Society for Parenteral and Enteral Nutrition guidelines 
on parenteral nutrition (surgery) were used to determine the patient’s 
requirements. These guidelines recommend 25-30 kcal/kg ideal 
body weight per day for energy, and 1.2-1.5 g/kg per day, or 20% of 
total energy intake for protein. A glucose to fat ratio of 50:50 up to 
70:30 of the non-protein energy is recommended.9
The patient’s energy needs were calculated as 25 kcal/kg ideal body 
weight/day non-protein energy, and his protein needs as 1.8 g/kg 
body weight/day. This resulted in 113 g protein per day, contributing 
20% to total energy. His carbohydrate needs were calculated at 70%, 
and fat at 30%, of the non-protein energy. His fluid requirement was 
calculated at 40 ml/kg/day, not accounting for drain losses. The 
patient was prescribed Intravenous Therapeutic Nutrition (ITN)® 
5003A from the commercial sector. 
Table II: Energy and macronutrient composition of total parenteral nutrition 
prescription (Intravenous Therapeutic Nutrition® 5003A)
Nutrient Content per 2 620 ml Dietary prescription
Energy 1 740 kcal NPE 1575 kcal (NPE)
Nitrogen 19.2 g 18 g (113 g protein)
Carbohydrate 300 g 275 g (70% NPE)
Fat 50 g 52.5 g (30% NPE)
NPE: non-protein energy
Nutritional management
On day 1, the patient was started on ITN® 5003A at 109 ml/hour. His 
intercostal drainage amounted to 550 ml for the day.
On day 2, the ICD draining was 1 000 mL/24 hrs. The TPN 
was subsequently continued at the maximum calculated rate of 
109 mL/hr as well as for the following two days (day 3 and 4 
post admission). The ITN® 5003A was continued at 109 ml/hour. 
No intercostal drainage was recorded on either day, but a repeat 
chest X-ray was performed on day 4. It was decided to initiate oral 
feeds and 2 (two) tins (500mL) of a semi-elemental product were 
prescribed. The product is rich in medium chain triglycerides (MCTs) 
with seventy percent (70%) of the fat content consisting of MCTs.
Simultaneously, the flow rate of the ITN® 5003A was decreased to 
70 ml/hour. This treatment was continued the following day (day 5) 
as no intercostal drainage had been recorded at that point of the 
patient’s daily clinical assessment.
On day 6, the intercostal drainage was recorded as 150 ml, the TPN 
discontinued, and the patient prescribed a low-fat diet which he 
tolerated well. 
Literature
A chylothorax can be defined as a leakage of chylous fluid from an 
abnormal or damaged thoracic duct or main branch thereof, after 
an injury or obstruction in the pleural cavity.5 It can also result from 
a cervical or thoracic node biopsy, resections (such as lung and 
pancreatic), other surgical procedures (such as oesophagectomy 
and neck dissection), as well as penetrating trauma, as was the case 
with this patient.5
The symptoms of a chylothorax are typically that of any pleural 
effusion, such as dyspnoea, coughing, chest discomfort and/or 
tachycardia, but the severity of the symptoms depends on the size 
of the chylothorax.5,10 An injury above the level of the fifth thoracic 
vertebra usually produces left-sided chylothorax and injuries below 
that level, right-sided chylothorax.10
Chyle consists of lymph from interstitial fluid and emulsified fat from 
intestinal lacteals and is collected and transported by the thoracic 
duct into the circulation.5,10 The thoracic duct usually originates from 
the cisterna Chyli which receives the fatty chyle from the intestinal 
lacteals and then transport the intestinal chyle containing digestive 
fat (mostly in the form of triglycerides) to the systemic venous 
system and lymphatics of the body.10 The lymph is derived from the 
gastro-intestinal tract as well as the liver and contains nutrients, 
lymphocytes, immunoglobulins and enzymes.10 
The flow of chyle through the thoracic duct varies from 1 ml/
minute to more than 200 ml/minute, with a total of 2 -4 l passing 
through it per day. The volume of chyle varies, depending on diet, 
intestinal absorption and degree of physical activity.10 Any activity 
that increases blood flow will increase chyle flow, including exercise, 
as well as any activities that will cause increased intra-abdominal 
pressure, such as coughing, for example.6 The milky appearance 
of the chyle is because almost all of the chyle originates from the 
Table III: The nutritional composition of chyle6,10
Component Concentration (per 100 ml)
Energy 20 kcal (84 kJ)
Total fat 0.4-3 g
Total cholesterol 1.68-5.69 mmol/l
Total protein 2.21-6 g
Albumin 1.2-4.1 g
Sugar 48-200 g
Electrolytes Similar to plasma
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intestinal lacteal system. Approximately 70% of all dietary fat passes 
through this system. The fat component of chyle consists of the 
end products of fat digestion, namely chylomicrons, triglycerides, 
cholesterol and fat-soluble vitamins, but fatty acids with less than 
10 carbons bypass this system, and are absorbed directly into the 
portal system. Chyle contains half the amount of protein as plasma, 
but is higher in albumin than plasma (Table III).5, 10 
The diagnosis of a chyle leak in post-traumatic pleural effusions is 
not well defined and the proposed methods vary from a chest x-ray 
or computed tomography (CT) of the thorax to assessing the drained 
pleural fluid with respect to volume, composition and colour.
When assessing the volume of drained pleural fluid, there is no 
consensus on what amount of chyle drainage warrants treatment or 
not. It is proposed that in the case of an oesophagectomy, drainage of 
more than 500 ml is indicative of a chyle leak. When determining the 
colour of the pleural fluid drainage, a change in colour after ingestion 
of a high-fat meal, or cessation of enteral feeding, should be sought 
specifically. After consumption of a high-fat food, such as cream, the 
pleural fluid can appear milky white or whitish in the presence of a 
chyle leak, but this can be misleading since in approximately half 
of cases with a chyle leak, the drainage can be reddish, yellow or 
serous.6,10 In some cases, methylene blue is added to the high-fat 
product, and if a chyle leak is present, the drained fluid will appear 
bluish-green. However, this practice might not be helpful in the case 
of a post-traumatic chylothorax since discoloration of pleural fluid 
can also occur in oesophageal perforation.10 Alternatively, tube feeds 
can be withheld for a time, and if the pleural fluid becomes clear, the 
presence of a chyle leak can be assumed.5
When determining the composition of the pleural drainage, 
an assessment should be made as to the presence of either 
chylomicron, triglyceride or lymphocyte count. The presence of 
chylomicrons aids in a definitive diagnosis with a composition 
of  more than 4% chylomicrons being diagnostic of a chyle leak 
whilst it can be assumed that a value under 4% is a portion of the 
fat breakdown during the normal healing process. Testing for the 
presence of chylomicrons can be carried out with Sudan® III stain or 
lipoprotein analysis of the pleural fluid itself, but unfortunately, this 
is not always available at medical centres. In such instances, the 
presence of triglyceride levels of more than 1.24 mmol/l can then be 
used to diagnose chylothorax, while a level below 0.56 mmol/l rules 
out such a diagnosis. If the level is between 0.56 mmol/l and 1.24 
mmol/l, a test should be conducted for the presence of chylomicrons 
to confirm the diagnosis.6 Alternatively, an elevated lymphocyte 
count of more than 50% the normal reference value is diagnostic 
of chylothorax.5,10
Some of the complications associated with a diagnosis of 
chylothorax include malnutrition, a compromised cell-mediated 
immune response and fat-soluble vitamin deficiencies, with 
possible symptoms of hypovolaemia, electrolyte disrturbances, 
hypoalbuminaemia, lymphopaenia and infection. Observed 
electrolyte abnormalities include metabolic acidosis, hypocalcaemia 
and hyponatraemia, as was observed in this patient.5,6,10 The cause 
of the complications that can develop relates to the composition of 
the chyle. For instance, the fat-soluble vitamin deficiencies that may 
occur in these patients relate to the loss of lipids in the chylous fluid. 
A large proportion of total body protein is transported in chylous fluid. 
Therefore, a chronic chyle leak results in protein loss, which, in turn, 
can result in fluid shifts and increased metabolic demand. Severe 
malnutrition, together with weight loss and muscle wasting, can 
occur in chronic chyle leak cases. A patient’s nutritional status will 
continue to deteriorate, or poor nutrititonal status will persist, unless 
definitive therapeutic measures are instituted to stop the leakage 
of chyle into the pleural space. In this case, the patient presented 
with a low urea and creatinine level, which was most probably 
as a result of increased protein losses. It should also be borne in 
mind that together with the loss of protein, there is also depletion 
of T cell lymphocytes and immunoglobulins. This diminished cell-
mediated immunity results in a compromised immune response and 
a predisposition to infections and increased risk of sepsis. Infections 
due to the chylothorax itself are very uncommon since chyle is 
naturally bacteriostatic.5,6,10
The management of chylothorax includes both medical (including 
medical nutrition therapy) management and surgical management. 
Once the patient is haemodynamically stable, a choice can be made 
on the specific therapy to be followed in accordance with the size 
of the chylothorax and the clinician’s preference.10 The medical 
management of a chyle leak is based on the theory that decreasing 
chyle flow allows for spontaneous closure of the chyle leak.5 
The initial step in management of a large chylothorax that often results 
in respiratory distress entails therapeutic thoracentesis, the removal 
of fluid from the space between the lining of the outside of the lungs 
(pleura) and the wall of the chest.5 The preferred method for this 
procedure is the insertion of an intercostal drain. During excessive 
drainage, patients are generally kept nil per os (npo) or prescribed a 
diet rich in MCTs since these fatty acids are absorped directly into 
the portal systrem. This approach resolving about 50% of congenital 
and traumatic chylothoraxis.10 An important adjuvant in the medical 
management of chylothorax is the use of octreotide, a synthetic 
somatostatin analogue, to reduce intestinal chyle production by 
reducing triglyceride absorption, and in this way, reducing the chyle 
leak.10 TPN is prescribed as part of the management of chronic 
chylothorax when there is a rapid loss of nutrients via the chyle. 
The most noticeable of these nutrients are protein, fat, fat-soluble 
vitamins and electrolytes, such as sodium, which was evident in this 
case. Therefore, medical treatment includes adequate drainage of 
the chest or other body cavities, bed rest and nutrition modification, 
including parenteral nutrition and the avoidance of fat.5,6
If conservative management is unsuccessful in the spontaneous 
closure of the fistula, surgical intervention may be necessary, 
especially in cases of a high-output fistula, defined as a daily chyle 
leak in excess of 1.5 l/per day (some sources advocate one litre 
per day as a cut-off value), if the chyle drainage is more than one 
litre/day for five consecutive days, or if the leak does not close 
spontaneously after 2-3 weeks of conservative management.6,10 The 
associated mortality is reported to decrease from 50% to 10% with 
active surgical intervention.10 Unfortunately, aggressive intervention 
involving reoperation can considerably increase morbidity and 
mortality, but if left untreated, the mortality rate of chylothorax is 
generally high.
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In summary, the goals of medical nutrition therapy (a “fat-free” 
or low-fat diet supplemented with MCT oil and fat-free oral 
supplements, enteral feeds containing a high percentage of MCTs, 
or the use of parenteral nutrition) are to decrease the production 
of chyle, replace fluid and electrolytes, and maintain and/or replete 
nutrition status.5,6 There is universal agreement that the nutritional 
status of the patient with a chylothorax worsens early after obtaining 
the pleural effusion, and that nutritional status should be stabilised 
with aggressive nutrition support.10
Although the primary focus of the nutrition support focus on the fat 
content of the diet, it has been shown that peristalsis and enteral 
intake, even ingesting water, can increase the lymph flow by 20%. The 
literature on the application of either enteral or parenteral nutrition, 
as part of the management of chylothorax is scarce, and based on 
small observational trials, small retrospective trials and case reports. 
Some of these studies suggest the use of enteral feeding with MCTs 
as management of chylothorax, while others advocate the use of 
TPN to resolve a chyle leak. In addition, parenteral nutrition has been 
reported to be associated with decreased duration of conservative 
therapy, an increased fistula closure rate and an improved nutrition 
response, when compared with the administration of enteral 
nutrition. In this regard, some studies suggest the successful 
application of enteral feeds containing MCTs to manage chyle leaks 
as this approach does not increase chyle flow, or delay healing of the 
chylous fistula or the development of complications.10
Conclusion
Nutrition support is of the utmost importance in the management of a 
patient who presents with a chylothorax to prevent the development 
of complications, such as malnutrition. However, guidelines for 
evidence-based medical nutrition therapy are lacking with regard 
to the optimal route, nutrient mix and duration of nutrition support 
needed to manage a chyle leak.
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